Ovation Science (XCNQ:OVAT) EV-to-EBIT : -2.13 (As of May. 24, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ovation Science EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ovation Science's Enterprise Value is C$1.67 Mil. Ovation Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.78 Mil. Therefore, Ovation Science's EV-to-EBIT for today is -2.13.

The historical rank and industry rank for Ovation Science's EV-to-EBIT or its related term are showing as below:

XCNQ:OVAT' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.67 Med: -2.57 Max: -0.17
Current: -2.13

During the past 7 years, the highest EV-to-EBIT of Ovation Science was -0.17. The lowest was -31.67. And the median was -2.57.

XCNQ:OVAT's EV-to-EBIT is ranked worse than
100% of 670 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs XCNQ:OVAT: -2.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ovation Science's Enterprise Value for the quarter that ended in Dec. 2023 was C$1.33 Mil. Ovation Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.78 Mil. Ovation Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -58.83%.

Ovation Science EV-to-EBIT Historical Data

The historical data trend for Ovation Science's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovation Science EV-to-EBIT Chart

Ovation Science Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-4.86

-7.60

-0.47

-0.94

-1.70

Ovation Science Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-0.94	-0.84	-0.72	-1.37	-1.70

Competitive Comparison of Ovation Science's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovation Science's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ovation Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ovation Science's EV-to-EBIT falls into.

Ovation Science EV-to-EBIT Calculation

Ovation Science's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1.669	/	-0.782
	=	-2.13

Ovation Science's current Enterprise Value is C$1.67 Mil.
Ovation Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.78 Mil.

Ovation Science (XCNQ:OVAT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ovation Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-0.782	/	1.3293145
	=	-58.83 %

Ovation Science's Enterprise Value for the quarter that ended in Dec. 2023 was C$1.33 Mil.
Ovation Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.78 Mil.

Ovation Science EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ovation Science's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovation Science (XCNQ:OVAT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ovation Science Inc (XCNQ:OVAT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

OVATF:USA

Address

625 Howe Street, Suite 1140, Vancouver, BC, CAN, V6C 2T6

Website

https://www.ovationscience.com

Ovation Science Inc is a Canada-based company mainly engaged in the business of sub-licensing rights to use Invisicare, a patented drug delivery technology used in topical and transdermal skin products containing hemp seed oil and cannabis products. The company also holds the right to manufacture, distribute, sell, market, sub-license and promote products formulated with Invisicare and containing cannabis products including cannabinoids, hemp seed oil and any synthetic derivatives of cannabis. It also develops formulas for skin product lines including topical and transdermal creams and lotions containing hemp seed oil and cannabis.

Executives

David K. Ryan

Director

Ovation Science (XCNQ:OVAT) Headlines

No Headlines